Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Status:
NOT_YET_RECRUITING
Trial end date:
2029-05-13
Target enrollment:
Participant gender:
Summary
This Phase 2 study is a 2-arm, multi-center, double-masked, placebo-controlled, 2:1 randomized sequential trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.
Phase:
PHASE2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)